An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)
NCT ID: NCT01483326
Last Updated: 2019-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
215 participants
OBSERVATIONAL
2010-12-31
2017-06-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
NCT01384461
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice
NCT01474291
A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy
NCT01705730
An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)
NCT01667458
A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
NCT01670045
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants in the ACT-SURE trial, or patients with moderate to severe rheumatoid arthritis starting or receiving RoActemra/Actemra
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jan Van Breemen Instituut
Amsterdam, , Netherlands
Gelre Ziekenhuis; Reumatology
Apeldoorn, , Netherlands
Rijnstate Ziekenhuis; Afdeling Reumatologie
Arnhem, , Netherlands
Amphia ziekenhuis, locatie langendijk
Breda, , Netherlands
Deventer ziekenhuis
Deventer, , Netherlands
MC groep - locatie Emmeloord
Emmeloord, , Netherlands
Scheper Ziekenhuis
Emmen, , Netherlands
Medisch Centrum Twente; Rheumatology
Enschede, , Netherlands
Ziekenhuis Walcheren; Reumatologie
Flushing, , Netherlands
Groene Hart Ziekenhuis
Gouda, , Netherlands
Röpcke Zweers ziekenhuis; Reumatologie
Hardenberg, , Netherlands
Tergooiziekenhuizen, loc. Hilversum
Hilversum, , Netherlands
Medisch Centrum Leeuwarden; Reumatology
Leeuwarden, , Netherlands
Maastricht University Medical Centre; Rheumatology
Maastricht, , Netherlands
St. Antonius Ziekenhuis; Pharmacy
Nieuwegein, , Netherlands
St. Maartenskliniek
Nijmegen, , Netherlands
Maasstadziekenhuis; Reumatologie
Rotterdam, , Netherlands
Vlietland Hospital
Schiedam, , Netherlands
Leyenburg Ziekenhuis; Internal Medecine
The Hague, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML25411
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.